Latest / This Week In Medicine / 10 27 2025

Transcript

10 27 2025 · This Week In Medicine

• 0:00
  [SPEAKER_00]: Welcome to this week in medicine, your filtered medical journal summary.
• 0:03
  [SPEAKER_00]: Looking to stay up to date with the latest medical research but short on time?
• 0:07
  [SPEAKER_00]: This week in medicine has you covered.
• 0:09
  [SPEAKER_00]: Our AI-generated podcast provides you with a convenient, on the go-solution to keep you informed about the most significant developments in the medicine field.
• 0:16
  [SPEAKER_00]: Each episode offers a filtered and concentrated summary of key journal articles, allowing you to stay informed without the need to sift through pages of research papers.
• 0:24
  [SPEAKER_00]: With this week in medicine, listening is faster than reading, and you can consume valuable medical knowledge while commuting, exercising, or during your daily routine.
• 0:32
  [SPEAKER_01]: Hi, this week in medicine, we will be discussing.
• 0:36
  [SPEAKER_01]: First we will be discussing articles in New England Journal of Medicine.
• 0:39
  [SPEAKER_01]: Hyprotonic saline or carbocystine in bronchiectasis.
• 0:43
  [SPEAKER_01]: Background Bronchiectasis guidelines are inconsistent with regard to the effectiveness of mucoactiv agents, and their use varies geographically.
• 0:52
  [SPEAKER_01]: Large trials are needed to assess safety and effectiveness.
• 0:55
  [SPEAKER_01]: Conclusions.
• 0:57
  [SPEAKER_01]: In participants with bronchi actresses, neither hypotonic saline nor carbosestine significantly reduced the mean incidence of pulmonary exacerbations over a period of 52 weeks.
• 1:09
  [SPEAKER_01]: Next article.
• 1:10
  [SPEAKER_01]: Aspirin patients with chronic coronary syndrome receiving oral anticoagulation
• 1:15
  [SPEAKER_01]: Background The appropriate antithromotic regimen for patients with chronic coronary syndrome, who are at high-athrothromotic risk and receiving long-term oral anti-coagulation remains unknown tongue clusions.
• 1:29
  [SPEAKER_01]: Among patients with chronic coronary syndrome at high-athrothromotic risk
• 1:34
  [SPEAKER_01]: who were receiving an oral anti-coagulant, the addition of aspirin led to a higher risk of cardiovascular death, myocardial infarction, stroke, systemic embolism, coronary refascularization, or acute limb ischemia than placebo, as well as higher risks of death from any cause and major bleeding.
• 1:53
  [SPEAKER_01]: Next article Common disease is in clinical cohorts, not always what they seem.
• 1:58
  [SPEAKER_01]: Background.
• 2:00
  [SPEAKER_01]: Mist diagnosis or underdiagnosis of rare diseases in patients with diagnoses of common diseases can lead to delayed or inappropriate treatments.
• 2:09
  [SPEAKER_01]: They're by complicating the management of both rare and common conditions.
• 2:13
  [SPEAKER_01]: Despite advances in molecular diagnostic techniques, the effect of rare diseases on the diagnosis of common diseases in research and clinical trials has not been comprehensively investigated, conclusions.
• 2:25
  [SPEAKER_01]: Our study shows the value of systematic genome sequencing in understanding the phenotypic heterogeneity of common diseases and identifying failure to diagnose rare diseases and highlights the benefits of deep molecular phenotyping, in clinical trials and patient care.
• 2:41
  [SPEAKER_01]: Next article.
• 2:43
  [SPEAKER_01]: Soatercept for pulmonary arterial hypertension within the first year after diagnosis.
• 2:49
  [SPEAKER_01]: Background.
• 2:53
  [SPEAKER_01]: reduces morbidity and mortality among patients with long-standing pulmonary arterial hypertension.
• 2:59
  [SPEAKER_01]: It's effects in patients with pulmonary arterial hypertension within the first year after diagnosis are unclear conclusions.
• 3:07
  [SPEAKER_01]: Among adults with pulmonary arterial hypertension who had received the diagnosis less than one year earlier, the addition of so-tator-sept to background therapy resulted in a lower risk of clinical worsening than placebo.
• 3:25
  [SPEAKER_01]: Next we will be discussing articles from Journal of American Medical Association.
• 3:30
  [SPEAKER_01]: Bioreasorbable versus Metallica Clutors for Transcatheter atrial septal defect closure.
• 3:36
  [SPEAKER_01]: Question, are bioreasorbable acclutors non-inferior to metallic devices for Transcatheter atrial septal defect, ASD, closure while exhibiting evidence of biodegradation, findings.
• 3:49
  [SPEAKER_01]: In this multi-center randomized non-inferiority trial, including 230 participants with secundum ASD, a bi-resorbable occluder demonstrated a comparable six-month ASD closure success rate, 96.5% versus 97.4% with a metallic occluder, and achieved near complete degradation, approximately 99.8% at two years.
• 4:12
  [SPEAKER_01]: Meaning a bio-resorbable occluder is not inferior to a metallic occluder for ASD closure, with near complete degradation by two years, offering a valuable transcatheter option.
• 4:29
  [SPEAKER_01]: Next, we will be discussing articles from Annals of Internal Medicine.
• 4:33
  [SPEAKER_01]: Trends in cancer incidents in younger and older adults, an international comparative analysis.
• 4:39
  [SPEAKER_01]: Background There is concern about widespread increases in cancer incidents rates in younger adults dot subjective.
• 4:47
  [SPEAKER_01]: To compare international cancer incidents trends in younger adults, age 20 to 49 years and older adults, age greater than or equal to 50 years, conclusion.
• 4:57
  [SPEAKER_01]: Cancer incidents rates increased for several cancer types in many of the countries studied.
• 5:02
  [SPEAKER_01]: However, other than colorectal cancer, these increases occurred in both younger and older adults.
• 5:08
  [SPEAKER_01]: These findings can help inform future research and clinical and public health guidelines.
• 5:19
  [SPEAKER_01]: Next we will be discussing articles from British Medical Journal.
• 5:22
  [SPEAKER_01]: Sodium glucose-co-transporter 2 inhibitors and risk of autoimmune-romatic diseases.
• 5:28
  [SPEAKER_01]: Objective to evaluate the use of sodium glucose-co-transporter 2, SGLT2, inhibitors and risk of autoimmune-romatic diseases and adults with type 2 diabetes, conclusions.
• 5:40
  [SPEAKER_01]: In this large cohort of adults with type 2 diabetes, SGLT-2 inhibitors or associated with an 11% lower risk of autoimmune rematic diseases compared with sulfonoloreas, these results suggest that SGLT-2 inhibitors may contribute to reducing the risk of autoimmune diseases.
• 5:59
  [SPEAKER_01]: This potential benefit, however, should be carefully weighed against known adverse events and concerns about tolerability.
• 6:08
  [SPEAKER_01]: as well as studies and patients with existing autoimmune rheumatic diseases are warranted to confirm and extend these observations.
• 6:22
  [SPEAKER_01]: Next we will be discussing articles in the field of hematoconcology.
• 6:26
  [SPEAKER_01]: Here are the articles from JAMA oncology.
• 6:29
  [SPEAKER_01]: Risk factors for valvealopathy among childhood cancer survivors.
• 6:34
  [SPEAKER_01]: Question, which treatments are associated with increased risk of symptomatic valvealer heart disease, VHD, in long-term childhood cancer survivors, findings.
• 6:44
  [SPEAKER_01]: In this case, control study of 225 case patients and 442 controls, heart radiation therapy, high cumulative anthrocycling doses, and exposure to platinum agents were associated with increased VHD risk.
• 6:58
  [SPEAKER_01]: The heart radiation therapy dose response was exponential, and the risk increased with longer follow-up, meaning the risk for VHD appears more strongly concentrated at
• 7:10
  [SPEAKER_01]: With exponential dose response associations observed for both exposures.
• 7:21
  [SPEAKER_01]: Next we will be discussing articles in the field of gastroenterology.
• 7:25
  [SPEAKER_01]: Here are the articles from gastroenterology.
• 7:28
  [SPEAKER_01]: Dietary fiber modulates the window of susceptibility to claustradiolide's difficile infection.
• 7:34
  [SPEAKER_01]: Background and aims.
• 7:36
  [SPEAKER_01]: claustradiolide's difficile epidemiology is rapidly evolving and understanding the factors that contribute to one's risk of seed difficile infection, CDI, is urgently needed.
• 7:50
  [SPEAKER_01]: We hypothesized that fiber modulates susceptibility to seed difficile after antibiotic exposure and investigated this using human specimens and mirin models conclusions.
• 8:02
  [SPEAKER_01]: Consumption of a low fiber diet after antibiotic use contributes to a prolonged susceptibility to CDI that corresponds to a perturbation in both microbiota and bilacid composition.
• 8:14
  [SPEAKER_01]: These results suggest that in the context of anti-biotic
• 8:18
  [SPEAKER_01]: Diet is a critical, modifiable risk factor for CDI susceptibility.
• 8:29
  [SPEAKER_01]: Here are the articles from clinical gastroenterology.
• 8:32
  [SPEAKER_01]: Prevalence and pathophysiology of loose tools and their impact on clinical severity and quality of life in women with fecal incontinence.
• 8:40
  [SPEAKER_01]: Objective.
• 8:41
  [SPEAKER_01]: To compare the impact of fecal consistency with anorectal sphincter dysfunctions on clinical severity and quality of life, call, in women with fecal incontinence, phi, background.
• 8:53
  [SPEAKER_01]: Phi affects up to 24% of middle-aged women,
• 8:58
  [SPEAKER_01]: Pathophysiological studies have focused more on sphincter and anorectal dysfunctions than on the role of fecal consistency to inclusions.
• 9:06
  [SPEAKER_01]: Fecal consistency of BSA greater than or equal to five significantly worsens clinical severity and call in women with fine.
• 9:14
  [SPEAKER_01]: Specific diagnostic and therapeutic approaches addressing loose stools are needed before any rehabilitation treatment.
• 9:27
  [SPEAKER_01]: Next we will be discussing articles in the field of infectious diseases.
• 9:31
  [SPEAKER_01]: Here are the articles from clinical infectious diseases.
• 9:35
  [SPEAKER_01]: Phase 1 evaluation of VH4,524,184, a third-generation integrated strand transfer inhibitor with an enhanced resistance profile.
• 9:46
  [SPEAKER_01]: Background Integrated strand transfer inhibitors, entities, have been fundamental to human
• 9:57
  [SPEAKER_01]: VH4,524,184, VH184 is a third-generation entity with long-acting potential currently in development for HIV1 treatment, conclusions.
• 10:11
  [SPEAKER_01]: These data support the safety and further development of VH184 as a third-generation
• 10:26
  [SPEAKER_01]: Next, we will be discussing articles in the field of rheumatology.
• 10:29
  [SPEAKER_01]: Here are the articles from Journal of Clinical rheumatology.
• 10:33
  [SPEAKER_01]: A novel scoring system for diagnosing systemic loopous erythematosis related sideopenias insights from a cohort study.
• 10:41
  [SPEAKER_01]: Objective
• 10:42
  [SPEAKER_01]: To develop a score for a diagnosis of sydopenias from systemic lupus erythematosis, SLE, activity and determine the usefulness of bone marrow, aspirate, and biopsy, BMA slash BMB, in this population tongue inclusion.
• 10:58
  [SPEAKER_01]: Disease activity and drug associated toxicity are the main causes of cytopenias in SLE patients.
• 11:04
  [SPEAKER_01]: We developed a scoring system with acceptable diagnostic performance to detect disease activity as the cause of cytopenias in patients with SLE.
• 11:19
  [SPEAKER_01]: Next we will be discussing articles in the field of cardiology.
• 11:22
  [SPEAKER_01]: Here are the articles from Circulation.
• 11:26
  [SPEAKER_01]: Redefining the genetic architecture of hypertrophic cardiomyopathy, role of intermediate effect variants.
• 11:32
  [SPEAKER_01]: Background.
• 11:34
  [SPEAKER_01]: hypertrophic cardiomyopathy.
• 11:36
  [SPEAKER_01]: HCM is a genetically heterogeneous disorder linked primarily to rare variants in sarcomeric genes.
• 11:43
  [SPEAKER_01]: Although recently certain non-sarcomeric genes have emerged as important contributors, non-mandalian genetic variants with reproducible moderate effect sizes and low penetrants, intermediate effect variants, EFs can play a crucial role in modulating disease expression.
• 11:59
  [SPEAKER_01]: Understanding the clinical impact of EFs is crucial to unravel the complex genetic architecture of HCMC conclusions.
• 12:07
  [SPEAKER_01]: EFs are present in 6.1% of HCMC cases and account for 4.8% of HCMC burden.
• 12:15
  [SPEAKER_01]: EFs also influence disease severity and outcomes, particularly when combined with monogenic disease causing variants.
• 12:22
  [SPEAKER_01]: Evaluation of EFs should be considered when HCMC genetic testing is performed.
• 12:32
  [SPEAKER_01]: Here are the articles from journals of the American College of Cardiology.
• 12:36
  [SPEAKER_01]: Trade-off between bleeding and eschemic events from left-ventricular assist devices, a EuroMax registry analysis.
• 12:44
  [SPEAKER_01]: Background A fully magnetically-levitated centrifugal flow pump
• 12:48
  [SPEAKER_01]: Heartmate 3, HM3, has significantly reduced thrombone ballic events in left ventricular assist device, LVAD, patients, potentially modifying the trade-off of eschemic and bleeding events, with current management strategies, the authors sought to characterize the opposing risk of eschemic and bleeding hemocompatibility-related adverse events, Reese, in leave-aid carriers with contemporary practice conclusions.
• 13:14
  [SPEAKER_01]: Advances in pump technology have significantly reduced rease in real-world DVA carriers and have reshaped the balance between eschemic and bleeding risks under current management.
• 13:24
  [SPEAKER_01]: The ongoing exceeding bleeding risk observed in contemporary practice underscores the urgent need for novel anti-thrombotic strategies that better align with the residual eschemic and bleeding profiles of levod patients.
• 13:43
  [SPEAKER_01]: from JAMA cardiology.
• 13:45
  [SPEAKER_01]: Age stratified effect of river oxiband monotherapy for atrial fibrillation in stable coronary artery disease opposed.
• 13:53
  [SPEAKER_01]: Hocchanalysis of the afire randomized clinical trial.
• 13:56
  [SPEAKER_01]: Question.
• 13:57
  [SPEAKER_01]: Does river oxiband monotherapy differ from river oxiband anti-platelet therapy in atrelated effects on major adverse cardiovascular or bleeding events in atrial fibrillation AF and stable coronary artery disease, CAD findings.
• 14:12
  [SPEAKER_01]: In this post-hocanalysis of the atrial fibrillation at ischemic events with Riveroxaban in patients with stable coronary artery disease, a fire, randomized clinical trial data, Riveroxaban monotherapy, showed consistent efficacy and safety across age groups, the net efficacy was more pronounced in older patients.
• 14:31
  [SPEAKER_01]: Whereas safety benefits were more evident in younger patients, meaning results reveal that river oxaban monotherapy yielded a consistent net clinical benefit across all age groups, especially in older patients with AF and stable CAD.
• 14:51
  [SPEAKER_01]: Next we will be discussing articles in the field of endocrinology.
• 14:55
  [SPEAKER_01]: Here are the articles from Journal of Clinical Endocrinology and Metabolism.
• 15:00
  [SPEAKER_01]: Using a composite summary of daily sex hormones to gauge time until menopause, a focus on pregnant-day-all-glucure night, PDG context.
• 15:09
  [SPEAKER_01]: The timing of a woman's final menstrual period, FMP, in relation to her age, is considered a valuable indicator of overall health, being associated with cardiovascular, bone health, reproductive, and general mortality outcomes dot objective.
• 15:24
  [SPEAKER_01]: This work aims to evaluate the relationship between hormones and the time to FMP when daily hormone trajectories are characterized by their one, entropy, and two,
• 15:34
  [SPEAKER_01]: Deviation from pre-menopausal slash stable cycle patterns, representing a textbook gold standard, G's, conclusion.
• 15:42
  [SPEAKER_01]: Since PDG is generally not considered a predictor slash descriptor of ovarian aging, this work validates the DTW slash fuzz and analytical framework, and introduces another metrics slash hormone to be used in FMP-related preventive care.
• 16:03
  [SPEAKER_01]: Here are the articles from diabetes care.
• 16:06
  [SPEAKER_01]: Differential effect of GLP-1 receptor agonists and SGLT-2 inhibitors on lower extremity amputation outcomes in type 2 diabetes, a nationwide retrospective cohort study.
• 16:18
  [SPEAKER_01]: Objective
• 16:19
  [SPEAKER_01]: To compare the risk of lower extremity amputations, liais, between new users of Glucogon-like peptide 1 receptor agonis, GLP1 Ross versus sodium glucose-co-transporter 2 inhibitors, SGLT2 is, conclusions.
• 16:35
  [SPEAKER_01]: GLP 1-Rot Treatment was associated with greater major amputation-free survival compared with SGLT-2I in people with type 2 diabetes, particularly in high-risk subgroups.
• 16:46
  [SPEAKER_01]: Perspective studies are needed to confirm findings and in form selection of glucose lowering therapies for people at risk for diabetes-related amputations.
• 17:01
  [SPEAKER_01]: Next we will be discussing articles in the field of neurology.
• 17:04
  [SPEAKER_01]: Here are the articles from neurology.
• 17:07
  [SPEAKER_01]: Soccer heading exposure dependent microstructural injury at depths of Solsea in adult amateur players.
• 17:14
  [SPEAKER_01]: Background and objectives.
• 17:16
  [SPEAKER_01]: Repetitive head impacts.
• 17:17
  [SPEAKER_01]: RHI's, in sports, are associated with adverse clinical and neuropathologic outcomes, but there is limited evidence from in vivo human imaging studies to inform risk assessment, exposure standards, and interventions.
• 17:31
  [SPEAKER_01]: We tested the association of RHI with in vivo microstructural disruption at the depths of cerebral sulci, a region vulnerable to trauma discussion.
• 17:40
  [SPEAKER_01]: Higher RHI exposure was associated with MRI measures of microstructural disruption at the depths of Solce in an exposure-dependent manner.
• 17:49
  [SPEAKER_01]: By contrast, deep white matter regions were relatively insensitive to RHI effects.
• 17:54
  [SPEAKER_01]: Diffusion MRI at the depths of Solce may serve as a more specific marker of RHI-related brain injury.
• 18:07
  [SPEAKER_01]: Next we will be discussing articles in the field of pulmonary and critical care.
• 18:11
  [SPEAKER_01]: Here are the articles from chest.
• 18:13
  [SPEAKER_01]: Effective ventilator mode on ventilator free days and critically ill adults.
• 18:18
  [SPEAKER_01]: A randomized clinical trial.
• 18:20
  [SPEAKER_01]: Background.
• 18:21
  [SPEAKER_01]: Whether the choice of ventilator mode affects outcomes for critically ill patients is unknown, research question.
• 18:28
  [SPEAKER_01]: What are the effects of three common ventilator modes?
• 18:31
  [SPEAKER_01]: Volume control versus pressure control versus adaptive pressure control, on death and duration of mechanical ventilation among critically ill adults, interpretation.
• 18:40
  [SPEAKER_01]: This pilot trial established the feasibility of conducting a cluster randomized crossover trial of ventilator mode among critically ill adults receiving invasive mechanical ventilation, and demonstrated differences in intermediate outcomes that warrant further investigation in a larger
• 19:03
  [SPEAKER_01]: Next we will be discussing articles in the field of nephrology.
• 19:06
  [SPEAKER_01]: Here are the articles from Clinical Journal of American Society of Nephrology.
• 19:11
  [SPEAKER_01]: Comparative effectiveness of Luber Prostone and Stools ofteners on risk of kidney outcomes and patients with CKD.
• 19:18
  [SPEAKER_01]: Luba Prostone has been suggested to exert kidney protective effects by improving the gut microbiome in animal studies.
• 19:25
  [SPEAKER_01]: This comparative effectiveness study examined the association of Luba Prostone versus softeners, use with kidney outcomes and patients with CKD.
• 19:34
  [SPEAKER_01]: Luba Prostone versus softeners, use was associated with a lower risk of progressive kidney function decline in patients with CKD and constipation.
• 19:50
  [SPEAKER_01]: Here are the articles from kidney-international reports randomized trial of Dappigliflozen in patients with non-diabetic stage 4 CKD.
• 19:58
  [SPEAKER_01]: Introduction Sodium glucose-co-transporter 2, SGLT2, inhibitors, are nephroprotective in patients with chronic kidney disease, CKD.
• 20:09
  [SPEAKER_01]: and mild to moderate renal insufficiency to inclusion.
• 20:13
  [SPEAKER_01]: Dapagliflo's and safely ameliorates compensatory, glomrolar hyperfiltration and proteinuria, and is glycosuric in non-diabetic patients with pre-terminal CKD.
• 20:24
  [SPEAKER_01]: GFR reduction is likely because of post-glomrolar vasodolation rather than pre-glomrolar viso-constriction.
• 20:31
  [SPEAKER_00]: Thank you for listening to this week in medicine, your filtered medical journal summary.
• 20:35
  [SPEAKER_00]: Have a great week ahead, stay blessed and be humane.